In contrast to conventional FXII inhibitors it does not interfere with other components of the contact activation system or plasmatic coagulation cascade potentially involved in stroke development such as kallikrein, FXa or the TF/FVIIa complex [15]. This evidence concerns the gene KLK4 and Stroke.